NCT01432704View on ClinicalTrials.gov

Colecalciferol as an Add-on Treatment to Subcutaneously-Administered Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

August 31, 2011

Conditions

Multiple Sclerosis

Interventions

DRUG

colecalciferol

Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months